Company newsVRTX
Explain this story: Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026: A $13.44 Billion Market by 2030 as Novartis, Vertex, CRISPR Therapeutics and Orchard Therapeutics Accelerate the Gene-Editing Race
The global autologous hematopoietic stem cell gene therapy market is projected to grow significantly, reaching $13.44 billion by 2030 from $5.23 billion in 2025, driven by advancements in gene-editing, increased investment in rare disease treatments, and personalized therapies. Key growth factors include commercialization of gene-editing therapies, regulatory approvals, adoption of personalized medicine, and infrastructure investments. North America was the largest regional market in 2025, with Asia-Pacific expected to be the fastest-growing region.
OtherGlobeNewswireSector and industry: HealthcareBiotechnologyTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
The global autologous hematopoietic stem cell gene therapy market is projected to grow significantly, reaching $13.44 billion by 2030 from $5.23 billion in 2025, driven by advancements in gene-editing, increased investment in rare disease treatments, and personalized therapies. Key growth factors include commercialization of gene-editing therapies, regulatory approvals, adoption of personalized medicine, and infrastructure investments. North America was the largest regional market in 2025, with Asia-Pacific expected to be the fastest-growing region.
Article tone: Positive This describes the words the journalist used. It is not a prediction, and not advice.